MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1182/blood.2022018971

Медицинская библиотека · Blood · 2024

Giroctocogene fitelparvovec gene therapy for severe hemophilia A: 104-week analysis of the phase 1/2 Alta study.

Leavitt Andrew D, Konkle Barbara A, Stine Kimo C, Visweshwar Nathan, Harrington Thomas J, Giermasz Adam, Arkin Steven, Fang Annie, Plonski Frank, Yver Anne, Ganne Florence, Agathon Delphine, Resa Maria de Los Angeles, Tseng Li-Jung, Di Russo Gregory, Cockroft Bettina M, Cao Liching, Rupon Jeremy

Клиническое исследование II фазыКлиническое исследование I фазыСтатьяПоддержка исследования: вне правительства СШАПеревод пока не подготовлен

Аннотация

Patients with hemophilia A require exogenous factor VIII (FVIII) or nonfactor hemostatic agents to prevent spontaneous bleeding events. Adeno-associated virus (AAV) vector-based gene therapy is under clinical investigation to enable endogenous FVIII production. Giroctocogene fitelparvovec is a recombinant AAV serotype 6 vector containing the coding sequence for the B-domain-deleted human F8 gene. In the ongoing phase 1/2, dose-ranging Alta study, 4 sequential cohorts of male participants with severe hemophilia A received a single IV dose of giroctocogene fitelparvovec. The primary end points are safety and changes in circulating FVIII activity. Interim results up to 214 weeks after treatment for all participants are presented. Eleven participants were dosed. Increases in alanine and aspartate aminotransferases were the most common treatment-related adverse events (AEs), which resolved with corticosteroid administration. Two treatment-related serious AEs (hypotension and pyrexia) were reported in 1 participant within 6 hours of infusion and resolved within 24 hours after infusion. At the highest dose level (3 × 1013 vg/kg; n = 5), the mean circulating FVIII activity level at week 52 was 42.6% (range, 7.8%-122.3%), and at week 104 it was 25.4% (range, 0.9%-71.6%) based on a chromogenic assay. No liver masses, thrombotic events, or confirmed inhibitors were detected in any participant. These interim 104-week data suggest that giroctocogene fitelparvovec is generally well tolerated with appropriate clinical management and has the potential to provide clinically meaningful FVIII activity levels, as indicated by the low rate of bleeding events in the highest dose cohort. This trial was registered at www.clinicaltrials.gov as #NCT03061201.

Для цитирования: Leavitt Andrew D, Konkle Barbara A, Stine Kimo C, Visweshwar Nathan, Harrington Thomas J, Giermasz Adam, Arkin Steven, Fang Annie, Plonski Frank, Yver Anne, Ganne Florence, Agathon Delphine, Resa Maria de Los Angeles, Tseng Li-Jung, Di Russo Gregory, Cockroft Bettina M, Cao Liching, Rupon Jeremy. Giroctocogene fitelparvovec gene therapy for severe hemophilia A: 104-week analysis of the phase 1/2 Alta study.. Blood. 2024. DOI: 10.1182/blood.2022018971.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.